Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRM-151 long-term open-label extension in idiopathic pulmonary fibrosis
NL-OMON52289Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of zinpentraxin alfa in idiopathic pulmonary fibrosis (IPF), sponsored by Roche. Started Dec 2021; status: active, not recruiting.
02
Drugs
zinpentraxin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON52289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52289.